

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/494,243	01/31/2000	Reid Warren von Borstel	1331-300	3188
23117 7	590 04/25/2005		EXAM	INER
NIXON & VANDERHYE, PC		OWENS JR, HOWARD V		
1100 N GLEBE ROAD 8TH FLOOR			ART UNIT	PAPER NUMBER
ARLINGTON, VA 22201-4714			1623	

DATE MAILED: 04/25/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Office Action Summary	09/494,243	VON BORSTEL ET AL.				
omoc Addon Gammary	Examiner	Art Unit				
The MAILING DATE of this communication	Howard V. Owens	1623				
The MAILING DATE of this communication Period for Reply	n appears on the cover sheet w	nn the correspondence address				
A SHORTENED STATUTORY PERIOD FOR R THE MAILING DATE OF THIS COMMUNICAT - Extensions of time may be available under the provisions of 37 of after SIX (6) MONTHS from the mailing date of this communication. If the period for reply specified above is less than thirty (30) days - If NO period for reply is specified above, the maximum statutory - Failure to reply within the set or extended period for reply will, by Any reply received by the Office later than three months after the earned patent term adjustment. See 37 CFR 1.704(b).	ION. CFR 1.136(a). In no event, however, may a on. s, a reply within the statutory minimum of thir period will apply and will expire SIX (6) MON statute, cause the application to become Al	reply be timely filed ty (30) days will be considered timely. NTHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on	the appeal brief filed on 9/10/0	4.				
3) Since this application is in condition for al	lowance except for formal mat	ters, prosecution as to the merits is				
closed in accordance with the practice un	der <i>Ex par</i> te Quayle, 1935 C.[). 11, 453 O.G. 213.				
Disposition of Claims						
4) Claim(s) 47-54 is/are pending in the appli	cation.					
4a) Of the above claim(s) is/are wit	thdrawn from consideration.					
5) Claim(s) is/are allowed.						
6) Claim(s) 47-54 is/are rejected.	· · · · · · · · · · · · · · · · · · ·					
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction a	and/or election requirement.					
Application Papers						
9) The specification is objected to by the Exa	aminer.					
10) The drawing(s) filed on is/are: a)	<u></u>	by the Examiner				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the c						
11) The oath or declaration is objected to by the	•	• • • • • • • • • • • • • • • • • • • •				
Priority under 35 U.S.C. § 119						
<u> </u>	roign priority under 25 LLC C. (2 110(a) (d) or (f)				
12) Acknowledgment is made of a claim for fo a) All b) Some * c) None of:	reign priority under 35 0.5.C.	3 119(a)-(d) or (i).				
	ments have been received					
1. Certified copies of the priority documents have been received.						
 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage 						
· · · · · · · · · · · · · · · · · · ·		received in this National Stage				
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
	2 S. and Sorting Sopies Het					
A4400h-n-n-4/n)						
Attachment(s) 1) Notice of References Cited (PTO-892)	A) M Intendeur (Summany (PTO 413)				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date						
3) Information Disclosure Statement(s) (PTO-1449 or PTO/S	SB/08) 5) D Notice of I	nformal Patent Application (PTO-152)				
Paper No(s)/Mail Date	6) Other:	<u> </u>				

Application/Control Number: 09/494,243

Art Unit: 1623

Response to Arguments

The following is in response to the appeal brief filed 9/10/04:

An action on the merits of claims 47-54 is contained herein below.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Interview

Applicant's representative Len Mitchard authorized an examiner's amendment to remove the term "preventing" from the claim language (in all occurrences). This authorization will presume to be in effect unless applicant in response to this office action files an amendment removing the term.

35 U.S.C. §112(1)

Pursuant to an appeals conference, the rejection of claims 47-54 as lacking written description has been overcome through applicant's arguments submitted in the appeal brief filed 9-10-04.

Double Patenting

The rejection of claims 47-54 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 3 of U.S. Patent No. 6,020,322 is maintained for the reasons of record. Although the conflicting claims are not identical, they are not patentably distinct from each other because they are both drawn to a method for treating mutagen induced cellular damage.

An obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but an examined application claim not is patentably distinct from the reference claim(s) because the examined claim is either anticipated by, or

Application/Control Number: 09/494,243

Art Unit: 1623

would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985). Although the conflicting claims are not identical, they are not patentably distinct from each other because claim 3 of '322 is generic to all that is recited in claims 47-54 of U.S. Patent No. 6,020,322. That is, claim 3 of U.S. Patent No. 6,020,322 falls entirely within the scope of claims 47-54. Specifically, the method of treating or preventing mutagen induced cellular damage as set forth in the instant claims encompasses the method of claim 3 of '022 where a method of treating mutagen induced cellular damage is claimed.

Howard V. Owens Patent Examiner Art Unit 1623

James O/. Wilson

Supervisory Patent Examiner

Technology Center 1600

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Howard Owens whose telephone number is (571) 272-0658. The examiner can normally be reached on Mon.-Fri. from 8:30 a.m. to 5 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the Supervisory Patent Examiner signing this action, James O. Wilson can be reached on (571) 272 - 0661.